Tara French – Managing Director – Cazaly Resources (ASX:CAZ) is a Perth based Australian diversified mineral exploration and resource development company.
Copyright 2023 – Finance News Network
Source: Finance News Network
05 Feb 2021 - Centuria Office REIT (ASX:COF) Fund Manager Grant Nichols discusses 1H21 highlights, the market conditions for leasing, and the outlook and trends for office markets.
Read More18 Nov 2020 - Shaw and Partners Chief Investment Officer Martin Crabb discusses to the current economic climate, inflation, and government and central bank reactions.
Read More22 Jun 2020 - An interview with Andrew Schwartz, Group Managing Director and Chief Investment Officer of Qualitas.
Read More01 Mar 2024 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results for using NYR-B103 to treat brain injuries.
Read More30 Jul 2024 - Andrew Penkethman - CEO & Managing Director - Ardea Resources (ASX:ARL) is an ASX-listed nickel resources company, with a large portfolio of 100%-controlled West Australian-based projects.
Read More03 Dec 2019 - Synertec Corporation Limited (ASX:SOP) Managing Director, Michael Carroll & CFO, David Harris talk FY19 results, market conditions and the outlook for specialist engineering and compliance services.
Read More01 Aug 2023 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses progress with the company's lithium project in California, including permitting, access to water and timeline ahead.
Read More01 Mar 2021 - Nutritional Growth Solutions Limited (ASX:NGS) Chairman Brian Leedman talks about the science behind the company's nutritional supplement formulae for children, which are designed to promote height and weight.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More
